Cargando…
Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles
Cytokine storm describes a life-threatening, systemic inflammatory syndrome characterized by elevated levels of proinflammatory cytokines and immune cell hyperactivation associated with multi-organ dysfunction. Matrix-bound nanovesicles (MBV) are a subclass of extracellular vesicle shown to down-reg...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198633/ https://www.ncbi.nlm.nih.gov/pubmed/37205761 http://dx.doi.org/10.1126/sciadv.adf9016 |
_version_ | 1785044774540017664 |
---|---|
author | Crum, Raphael J. Huckestien, Brydie R. Dwyer, Gaelen Mathews, Lisa Nascari, David G. Hussey, George S. Turnquist, Heth R. Alcorn, John F. Badylak, Stephen F. |
author_facet | Crum, Raphael J. Huckestien, Brydie R. Dwyer, Gaelen Mathews, Lisa Nascari, David G. Hussey, George S. Turnquist, Heth R. Alcorn, John F. Badylak, Stephen F. |
author_sort | Crum, Raphael J. |
collection | PubMed |
description | Cytokine storm describes a life-threatening, systemic inflammatory syndrome characterized by elevated levels of proinflammatory cytokines and immune cell hyperactivation associated with multi-organ dysfunction. Matrix-bound nanovesicles (MBV) are a subclass of extracellular vesicle shown to down-regulate proinflammatory immune responses. The objective of this study was to assess the efficacy of MBV in mediating influenza-induced acute respiratory distress syndrome and cytokine storm in a murine model. Intravenous administration of MBV decreased influenza-mediated total lung inflammatory cell density, proinflammatory macrophage frequencies, and proinflammatory cytokines at 7 and 21 days following viral inoculation. MBV decreased long-lasting alveolitis and the proportion of lung undergoing inflammatory tissue repair at day 21. MBV increased the proportion of activated anti-viral CD4(+) and CD8(+) T cells at day 7 and memory-like CD62L(+) CD44(+), CD4(+), and CD8(+) T cells at day 21. These results show immunomodulatory properties of MBV that may benefit the treatment of viral-mediated pulmonary inflammation with applicability to other viral diseases such as SARS-CoV-2. |
format | Online Article Text |
id | pubmed-10198633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-101986332023-05-20 Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles Crum, Raphael J. Huckestien, Brydie R. Dwyer, Gaelen Mathews, Lisa Nascari, David G. Hussey, George S. Turnquist, Heth R. Alcorn, John F. Badylak, Stephen F. Sci Adv Biomedicine and Life Sciences Cytokine storm describes a life-threatening, systemic inflammatory syndrome characterized by elevated levels of proinflammatory cytokines and immune cell hyperactivation associated with multi-organ dysfunction. Matrix-bound nanovesicles (MBV) are a subclass of extracellular vesicle shown to down-regulate proinflammatory immune responses. The objective of this study was to assess the efficacy of MBV in mediating influenza-induced acute respiratory distress syndrome and cytokine storm in a murine model. Intravenous administration of MBV decreased influenza-mediated total lung inflammatory cell density, proinflammatory macrophage frequencies, and proinflammatory cytokines at 7 and 21 days following viral inoculation. MBV decreased long-lasting alveolitis and the proportion of lung undergoing inflammatory tissue repair at day 21. MBV increased the proportion of activated anti-viral CD4(+) and CD8(+) T cells at day 7 and memory-like CD62L(+) CD44(+), CD4(+), and CD8(+) T cells at day 21. These results show immunomodulatory properties of MBV that may benefit the treatment of viral-mediated pulmonary inflammation with applicability to other viral diseases such as SARS-CoV-2. American Association for the Advancement of Science 2023-05-19 /pmc/articles/PMC10198633/ /pubmed/37205761 http://dx.doi.org/10.1126/sciadv.adf9016 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Crum, Raphael J. Huckestien, Brydie R. Dwyer, Gaelen Mathews, Lisa Nascari, David G. Hussey, George S. Turnquist, Heth R. Alcorn, John F. Badylak, Stephen F. Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles |
title | Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles |
title_full | Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles |
title_fullStr | Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles |
title_full_unstemmed | Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles |
title_short | Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles |
title_sort | mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198633/ https://www.ncbi.nlm.nih.gov/pubmed/37205761 http://dx.doi.org/10.1126/sciadv.adf9016 |
work_keys_str_mv | AT crumraphaelj mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles AT huckestienbrydier mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles AT dwyergaelen mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles AT mathewslisa mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles AT nascaridavidg mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles AT husseygeorges mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles AT turnquisthethr mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles AT alcornjohnf mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles AT badylakstephenf mitigationofinfluenzamediatedinflammationbyimmunomodulatorymatrixboundnanovesicles |